South Korea has decided to reimburse Merck & Co. Inc.'s Keytruda (pembrolizumab) and Bristol-Myers Squibb Co.'s Opdivo (nivolumab), marking its first reimbursement of immuno-oncology drugs, to sharply lower the financial burden of patients and improve market access of these drugs.
However, reimbursement has been limited to certain patient populations to prevent misuse of the drugs
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?